# EDGAR Filing Document

**Accession Number:** 0001723059
**File Stem:** 0001213900-26-047207
**Filing Date:** 2026-4
**Character Count:** 14527
**Document Hash:** e743c5c581893ccd29110fb776f8fba1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-047207.hdr.sgml**: 20260424

**ACCESSION NUMBER**: 0001213900-26-047207

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20260424

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260424

**DATE AS OF CHANGE**: 20260423

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Bio Essence Corp
- **CENTRAL INDEX KEY:** 0001723059
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 943349551
- **STATE OF INCORPORATION:** CA
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-56263
- **FILM NUMBER:** 26890159

**BUSINESS ADDRESS:**
- **STREET 1:** 2955 MAIN STREET
- **STREET 2:** STE 300
- **CITY:** IRVINE
- **STATE:** CA
- **ZIP:** 92614
- **BUSINESS PHONE:** 888-816-1494

**MAIL ADDRESS:**
- **STREET 1:** 2955 MAIN STREET
- **STREET 2:** STE 300
- **CITY:** IRVINE
- **STATE:** CA
- **ZIP:** 92614

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 8-K**

**Current Report**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

April 24, 2026

(Date of Report)

**<u>BIO ESSENCE CORP.</u>**

(EXACT NAME OF REGISTRANT AS SPECIFIED IN CHARTER)

---

| | | |
|:---|:---|:---|
| **California** | **000-56263** | **94-3349551** |
| (STATE OR OTHER JURISDICTION OF<br> INCORPORATION OR ORGANIZATION) | (COMMISSION FILE NO.) | (IRS EMPLOYEE <br> IDENTIFICATION NO.) |

---

**2955 Main Street, Suite 300, Irvine, CA 92618**

(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)

**(949) 706-9966**

(ISSUER TELEPHONE NUMBER)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<u>see</u> General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| N/A | N/A | N/A |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter. ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 1.01 Entry into a Material Definitive Agreement** 

On April 20, 2026, Bio Essence Corp., a California corporation ("Company") entered into a Asset Purchase Agreement ("APA") with Zhituo Software Co., Limited, a company incorporated under the laws of Hong Kong ("Zhituo"). Under the APA, the Company acquires ownership of certain software known as MediFlow AI, previously known as AcuVital, along with all of its software source code, system architecture, data, APOs, frameworks, and other technical information and data, the full extent of which is listed in Article II, Section 2.2 of the APA (collectively the "Software"), which is attached hereto as an Exhibit. In exchange for the acquisition of the Software, Zhituo will receive compensation by way of the issuance of common stock of the Company in an amount equal to fair market value of Three Million Five Hundred Thousand Dollars ($3,500,000). The valuation and number of shares is subject to approval by the Company's Board of Directors.

Prior to the initiation of this transaction, there was no material relationship between the Company and Zhituo. A copy of the APA and the Consent Resolution of the Board of Directors approving the terms of the APA are attached hereto as an Exhibit.

**Item 9.01 Financial Statements and Exhibits**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | [Consent Resolution and Asset Purchase Agreement](ea028754801ex99-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| **BIO ESSENCE CORP.** | **BIO ESSENCE CORP.** |
| /s/ Yin Yan | /s/ Yin Yan |
| By: | Yin Yan |
| Its: | Chief Executive Officer |
| Dated: April 24, 2026 | Dated: April 24, 2026 |

---

## Exhibit 99.1

**Exhibit 99.1**

**CONSENT RESOLUTIONS OF THE BOARD OF DIRECTORS (BIO ESSENCE CORP.)**

NOW COMES the Board of Directors for Bio Essence Corp., a California corporation (the "Company"), hereby consents pursuant to Article II, Section 13 of the Bylaws to the following action in lieu of a meeting:

WHEREAS, the Company's executives have entered into negotiations with Zhituo Software, Co., Ltd, to purchase software known as MediFlow AI ("***Software***");

WHEREAS, those negotiations have resulted in the production of an Asset Purchase Agreement, attached hereto as **Exhibit A**, that the Company's officers believe is in the best interest of the Company to execute to memorialize the purchase and acquisition of the Software ("***APA***");

WHEREAS, the Board of Directors consents to the acquisition of the Software pursuant to the terms of the APA;

NOW THEREFORE, the Board of Directors consent to the following actions:

RESOLVED, the Board of Directors approves the terms of the APA, and the Company's Chief Executive Officer, Yin Yan, has authorization to execute the same.

RESOLVED, the Board of Directors hereby ratifies all prior acts of the Company, its officers, and its directors as being in the best interest of the Company.

***[Signatures on Next Page]***

 ****

SIGNATURE PAGE FOR CONSENT RESOLUTIONS OF THE BOARD OF DIRECTORS<br> (BIO ESSENCE CORP.)

Approved for entry in the books and records of the Corporation.

Dated: April 21, 2026

---

| | |
|:---|:---|
| /s/ Yin Yan | /s/ Yin Yan |
| By: | Yin Yan |
| Its: | Director |
| /s/ Siyavash Fooladian | /s/ Siyavash Fooladian |
| By: | Siyavash Fooladian |
| Its: | Director |
| /s/ William Sluss | /s/ William Sluss |
| By: | William Sluss |
| Its: | Director |

---

**Exhibit A**

(Beginning on Following Page)

**ASSET PURCHASE AGREEMENT**

This Asset Purchase Agreement (this **"Agreement"**) is made as of _April 20_**, 2026** (the **"Effective Date"**), by and between:

**Bio Essence Corporation**, a corporation incorporated under the laws of the United States and listed on the OTCQB Market (**"Buyer"**),

and

**Zhituo Software Co., Limited**, a company incorporated under the laws of Hong Kong (**"Seller"**).

Buyer and Seller may be referred to individually as a **"Party"** and collectively as the **"Parties."**

<u>ARTICLE I</u>

**PARTIES**

**Buyer:**

Bio Essence Corporation (BIOE)

**Seller:**

Zhituo Software Co., Limited

<u>ARTICLE II</u>

**PURCHASED ASSETS**

2.1 Sale of Assets.

Subject to the terms and conditions of this Agreement, Seller agrees to sell, assign, transfer, convey, and deliver to Buyer, and Buyer agrees to purchase from Seller, all of Seller's right, title, and interest in and to the MediFlow AI (previously "AcuVital") platform (the **"Purchased Assets"**).

2.2 Purchased Assets Defined.

The Purchased Assets include, without limitation:

● All software source code and object code;

● System architecture, databases, algorithms, APIs, and technical frameworks;

● Documentation, specifications, and development materials;

● Domain names, trademarks, service marks, logos (if any), and associated goodwill;

● All intellectual property rights, including copyrights, trademarks, trade secrets, and other proprietary rights; and

● All other assets used exclusively in connection with the MediFlow AI (previously "AcuVital") platform.

Page **1** of **5**

**ASSET PURCHASE AGREEMENT**

2.3 Excluded Assets.

No equity interest in Seller is transferred pursuant to this Agreement. All assets not expressly included in the Purchased Assets are excluded.

<u>ARTICLE III</u>

**PURCHASE PRICE**

3.1 Purchase Price.

The aggregate purchase price for the Purchased Assets (the **"Purchase Price"**) shall consist of:

**Equity Consideration:** shares of restricted common stock of Buyer that are equivalent to USD $3,500,000 valued at fair market value as approved by Buyer's Board of Directors.

3.2 Allocation.

The Parties shall allocate the Purchase Price among the Purchased Assets in a manner consistent with applicable tax laws.

<u>ARTICLE IV</u>

**SHARE CONSIDERATION**

4.1 Securities Law Compliance.

Any shares issued as equity consideration are not compensation for services and shall be issued pursuant to an exemption from registration under Section 4(a)(2) of the U.S. Securities Act of 1933 and/or Regulation D promulgated thereunder.

4.2 Restricted Securities.

Such shares shall constitute "restricted securities" as defined under Rule 144 and shall be subject to all applicable transfer restrictions. Buyer makes no representation or warranty regarding liquidity, resale, or market value.

<u>ARTICLE V</u>

**INTELLECTUAL PROPERTY ASSIGNMENT**

5.1 Ownership.

Seller represents and warrants that it owns all rights, title, and interest in and to the Purchased Assets, free and clear of all liens and encumbrances.

5.2 Assignment.

At Closing, Seller hereby irrevocably assigns, transfers, and conveys to Buyer all intellectual property rights in the Purchased Assets, including all worldwide rights therein, whether now existing or hereafter arising.

Page **2** of **5**

**ASSET PURCHASE AGREEMENT**

5.3 Further Assurances.

Seller agrees to execute such further documents and take such further actions as may reasonably be required to perfect Buyer's ownership of the Purchased Assets.

<u>ARTICLE VI</u>

**REPRESENTATIONS AND WARRANTIES**

6.1 Seller Representations.

Seller represents and warrants that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Seller has full power and authority to enter into this Agreement and consummate the transactions contemplated hereby;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The execution and performance of this Agreement do not violate any agreement to which Seller is a party;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) The Purchased Assets do not infringe, misappropriate, or violate any third-party intellectual property rights; and.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (d) There are no undisclosed material liabilities relating to the Purchased Assets.

6.2 Buyer Representations.

Buyer represents and warrants that it has full power and authority to enter into this Agreement and perform its obligations hereunder.

<u>ARTICLE VII</u>

**CLOSING**

7.1 Closing.

The closing of the transactions contemplated by this Agreement (the **"Closing"**) shall occur on or before 45 days of the signing of the agreement, or a date mutually agreed upon by the Parties, subject to satisfaction or waiver of all conditions precedent.

7.2 Conditions Precedent.

Conditions to Closing include, without limitation:

● Approval by Buyer's Board of Directors; and

● Delivery of all required assignment, transfer, and closing documents.

<u>ARTICLE VIII</u>

**TAX MATTERS**

Each Party shall be responsible for its own taxes arising from this Agreement unless otherwise required by applicable law.

Page **3** of **5**

**ASSET PURCHASE AGREEMENT**

<u>ARTICLE IX</u>

**GOVERNING LAW AND VENUE**

This Agreement shall be governed by and construed in accordance with the laws of the State of California, without regard to its conflict of laws principles. Any action arising out of or relating to this Agreement shall be brought exclusively in the state or federal courts located within the State of California.

<u>ARTICLE X</u>

**ENTIRE AGREEMENT**

This Agreement constitutes the entire agreement between the Parties with respect to the subject matter hereof and supersedes all prior or contemporaneous agreements, understandings, or negotiations, whether written or oral.

<u>ARTICLE XI</u>

**INDEMNIFICATION**

11.1 Seller Indemnification.

Seller shall indemnify, defend, and hold harmless Buyer and its affiliates from and against all losses, claims, damages, liabilities, costs, and expenses (including reasonable attorneys' fees) arising out of or resulting from:

&nbsp;&nbsp;&nbsp;&nbsp;(a) any breach of Seller's representations or warranties;

&nbsp;&nbsp;&nbsp;&nbsp;(b) any breach of Seller's covenants; or

&nbsp;&nbsp;&nbsp;&nbsp;(c) any claim that the Purchased Assets infringe any third-party
rights.

11.2 Buyer Indemnification.

Buyer shall indemnify Seller for losses arising from Buyer's breach of this Agreement.

<u>ARTICLE XII</u>

**SURVIVAL**

Seller's representations and warranties shall survive the Closing for eighteen (18) months, except that representations relating to intellectual property, authority, title to assets, and taxes shall survive for the applicable statute of limitations. Covenants intended to survive shall survive in accordance with their terms.

<u>ARTICLE XIII</u>

**LIMITATION OF LIABILITY**

Except for claims arising from fraud, willful misconduct, or breaches of intellectual property representations, neither Party shall be liable for any indirect, incidental, consequential, special, or punitive damages.

Page **4** of **5**

<u>SIGNATURES</u>

---

| | |
|:---|:---|
| **BUYER:** | **BUYER:** |
| Bio Essence Corporation (BIOE) | Bio Essence Corporation (BIOE) |
| By: | /s/ Yin Yan |
| Name: | Yin Yan |
| Title: | CEO |
| Date: | 04/20/2026 |
| **SELLER:** | **SELLER:** |
| Zhituo Software Co., Limited | Zhituo Software Co., Limited |
| By: | /s/ Dangwei Zhu |
| Name: | Dangwei Zhu |
| Title: | CEO |
| Date: | 04/21/2026 |

---

Page **5** of **5**